The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Revenue | 33,255 | - |
| Less cost of sales | 11,263 | - |
| Gross profit | 21,992 | - |
| General and administrative | 7,071 | - |
| Sales and marketing | 11,746 | - |
| Research and development | 634 | - |
| Interest expense | 2,953 | - |
| Unrealized foreign currency translation loss (gain) | -56 | - |
| Other expense | -16 | - |
| Provision for income taxes | 257 | - |
| Net income (loss) | 1,308 | 3,608 |
| Depreciation and amortization | 1,161 | 2,243 |
| Provision for reserve on accounts receivable | - | 395 |
| Gain on disposal of fixed assets | -33 | 49 |
| Non-cash interest | 126 | 289 |
| Stock-based compensation | 641 | 1,524 |
| Provision for expected credit losses | 568 | - |
| Provision for excess and obsolete inventory | 828 | 490 |
| Other | 22 | 46 |
| Accounts receivable | -1,234 | 6,873 |
| Inventories | 1,440 | 1,349 |
| Prepaid and other assets | 33 | -347 |
| Accounts payable | -399 | -880 |
| Accrued liabilities | 958 | 2,763 |
| Net cash provided by (used in) operating activities | 4,612 | 2,554 |
| Purchases of property and equipment | 430 | 1,557 |
| Proceeds from sale of fixed assets | 109 | 97 |
| Advances from pending sale of coflex/cofix assets and international hardware business | 5,000 | - |
| Net cash provided by (used in) investing activities | 4,679 | -1,460 |
| Payments on financing leases | 17 | 34 |
| Borrowings on line of credit | 25,761 | 51,812 |
| Repayments on line of credit | 26,460 | 51,925 |
| Proceeds from issuance of long term debt | - | 0 |
| Payments on long-term debt | 5,000 | - |
| Debt issuance costs | 0 | 49 |
| Payments of taxes from withholding of common stock on settlement of restricted stock units | 55 | 61 |
| Net cash (used in) provided by financing activities | -5,771 | -257 |
| Effect of exchange rate changes on cash and cash equivalents and restricted cash | 84 | -21 |
| Net change in cash and cash equivalents and restricted cash | 3,604 | 816 |
| Cash and cash equivalents at beginning of period | 6,221 | - |
| Cash and cash equivalents at end of period | 10,641 | - |
Xtant Medical Holdings, Inc. (XTNT)
Xtant Medical Holdings, Inc. (XTNT)